Canagliflozin as an Initial Therapy in Drug-Naïve Subjects With Type 2 Diabetes Mellitus: A Potential Involvement of Atherogenic Lipids in Its Glycemic Efficacy

Drugs in R and D - United Kingdom
doi 10.1007/s40268-017-0179-7
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Initial Sulfonylurea Use and Subsequent Insulin Therapy in Older Subjects With Type 2 Diabetes Mellitus

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2012English

Glycemic Control in Type 2 Diabetes Mellitus Patients

Chattagram Maa-O-Shishu Hospital Medical College Journal
2012English

Prehypertension Increases the Risk of Atherosclerosis in Drug-Naïve Japanese Patients With Type 2 Diabetes Mellitus

PLoS ONE
Multidisciplinary
2018English

The Cost-Effectiveness of Canagliflozin Versus Sitagliptin as Third-Line Therapy in Type 2 Diabetes Mellitus (T2dm) in a Canadian Setting

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Efficacy and Safety of Colesevelam in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Receiving Insulin-Based Therapy

Archives of Internal Medicine
2008English

Efficacy and Safety of Canagliflozin Compared With Placebo in Older Patients With Type 2 Diabetes Mellitus: A Pooled Analysis of Clinical Studies

BMC Endocrine Disorders
MedicineEndocrinologyMetabolismDiabetes
2014English

Effect of Canagliflozin on Serum Uric Acid in Patients With Type 2 Diabetes Mellitus

Diabetes, Obesity and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2015English

Canagliflozin: Effects in Overweight and Obese Subjects Without Diabetes Mellitus

Obesity
NutritionEndocrinologyDieteticsMedicineMetabolismDiabetes
2013English

Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients With Type 2 Diabetes Mellitus

Advances in Therapy
MedicinePharmacology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy